Scarica l'app Stockscreener
227.87
0.25%
0.56
Dopo l'orario di chiusura:
227.87
Ascendis Pharma A S Borsa (ASND) Ultime notizie
Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today - Benzinga
Form 4 Ascendis Pharma A/S For: 29 September By Investing.com - Investing.com Nigeria
ASND Price Today: Ascendis Pharma A/S Stock Price, Quote & Chart | MEXC - MEXC
Ascendis Pharma (ASND) Could Be 28% Undervalued As It Reclaims TransCon Rights - Simply Wall Street
Enterprise value of Ascendis Pharma A/S – FWB:A710 - TradingView
Total operating expenses of Ascendis Pharma A/S – FWB:A710 - TradingView
Ascendis Pharma Falls as Investors Reassess Novo Rights Reversion and Pipeline Execution Risk - moomoo.com
Ascendis Pharma (NASDAQ: ASND) Severs Novo Nordisk Tie To Take Full Control Of TransCon Metabolic Pipeline - foreignpolicyjournal.com
Ascendis Pharma A/S (ASND) Stock Price, News, Quote & History - Yahoo! Finance Canada
symbol__ Stock Quote Price and Forecast - CNN
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $273 - moomoo.com
Ascendis Pharma A/S (ASND) Stock Analysis: Exploring a Potential 31.52% Upside in Biotech Sector - DirectorsTalk Interviews
Ascendis Pharma (ASND) Authorizes $400M Share Buyback - Yahoo Finance
Ascendis Pharma (ASND) Regains Exclusive Rights To Key TransCon Metabolic Programs - Yahoo Finance
Ascendis Pharma (ASND) Stock Looks Near Fair Value On Infant Trial Data - Simply Wall Street
Ascendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost? - Yahoo Finance
Ascendis faces financial setback after patent dispute – Yet the CEO sees the outcome as a victory - medwatch.com
Novo Nordisk ends $285M TransCon partnership with Ascendis, which will now develop monthly obesity drug itself - Dealroom
Ascendis Pharma: Back To Full Independence (NASDAQ:ASND) - Seeking Alpha
Ascendis Has Capacity To Execute Alone After Termination of Novo Nordisk Collaboration, Wedbush Says - finance.yahoo.com
H.C. Wainwright reiterates Ascendis Pharma stock rating on Novo deal end By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Ascendis Pharma stock rating on Novo deal end - Investing.com
Ascendis regains obesity rights as Novo exits monthly GLP-1 deal - thepharmaletter.com
Ascendis CEO after scrapped Novo partnership: Big mistake to be dependent on Big Pharma - medwatch.com
Ascendis Pharma (ASND) Reclaims Global TransCon Rights For Obesity And Heart Disease - simplywall.st
Why Is Ascendis Pharma Stock Trading Lower on Tuesday? - TradingView
Ascendis Pharma A/S Stock (ASND) Moved Down by 12.08% on Sep 15: What Signal Does It Send? - TradingKey
Ascendis Pharma Slides as Investors Weigh Novo Rights Reversion Despite Buyback - Quiver Quantitative
Ascendis Pharma Cut to Outperform From Strong Buy by Raymond James - Moomoo
Ascendis Pharma at Morgan Stanley conference: cash flow, growth and rights - Investing.com
Novo still seeks a long-acting treatment after scrapped deal with Ascendis - medwatch.com
Ascendis Pharma (NASDAQ: ASND) board okays discretionary $400M share buyback - Stock Titan
Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis - Fierce Biotech
Ascendis Pharma Regains Rights to Obesity Drug, Discloses $400 Million Share Buyback - marketscreener.com
Novo Nordisk deal ends as Ascendis (NASDAQ: ASND) takes back obesity drug rights, with more programs shifting over - Stock Titan
Novo Nordisk, Ascendis Pharma End Metabolic, Cardiovascular Partnership - marketscreener.com
Ascendis Pharma authorizes $400 million share buyback program - Investing.com
Ascendis Pharma Authorizes Up to $400 Million Share Repurchase Program - Quiver Quantitative
Ascendis plans a once-monthly obesity drug after its Novo deal ends - Stock Titan
$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today - benzinga.com
Ascendis Pharma (NASDAQ:ASND): Strong Growth Meets a High-Quality Technical Setup - ChartMill
Consensus Analysis | Ascendis Pharma | 2026-09-14 - Biostock
Ascendis Pharma A/S (ASND) Stock Analysis: Is the 18.6% Upside a Green Light for Investors? - DirectorsTalk Interviews
Ascendis Pharma authorizes $400 million share buyback program By Investing.com - Investing.com UK
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis - Yahoo Finance
Ascendis Pharma (ASND) ReACHin Data Keeps The Bull Case Alive As Valuation Questions Linger - simplywall.st
TD Cowen reiterates Buy on Ascendis Pharma stock on infant data By Investing.com - Investing.com Nigeria
Ascendis Pharma (NASDAQ: ASND) Issues 29,380 Employee Warrants at $270.09 Exercise Price - Kalkine Media
Insider Decision: Mads Bodenhoff Offloads $810K Worth Of Ascendis Pharma Stock - Benzinga
Ascendis Pharma Says Growth Drug Shows Benefits in Infants - Benzinga
H.C. Wainwright reiterates Ascendis Pharma stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Ascendis Pharma stock rating at buy - Investing.com
TD Cowen reiterates Buy on Ascendis Pharma stock on infant data - investing.com
BMO reiterates Ascendis Pharma stock rating on infant trial data - investing.com
BMO reiterates Ascendis Pharma stock rating on infant trial data By Investing.com - Investing.com India
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):